Business > Class Notes > SWOT Analysis for Acorda Therapeutics, Inc. With the Latest (2019) Company Profile (All)

SWOT Analysis for Acorda Therapeutics, Inc. With the Latest (2019) Company Profile

Document Content and Description Below

COMPANY OVERVIEW Acorda Therapeutics (Acorda or 'the company') is a commercial-stage biotechnology company. It is engaged in the development and marketing of therapies to help restore function in p... ersons with spinal cord injury, multiple sclerosis and related conditions of the central nervous system. The company also offers various pipeline products to neurological therapies including heart failure, migraine, Primary Sclerosing Cholangitis, MS, spinal cord injury and various other disorders. Acorda's product portfolio are marketed under Zanaflex, Ampyra or Fampyra (dalfampridine); and Qutenza.The company primarily operates in the US, where it is headquartered in Ardsley, New York. SWOT ANALYSIS Acorda Therapeutics (Acorda or 'the company') is a commercial-stage biotechnology company engaged in the development of therapies for multiple sclerosis (MS), spinal cord injury and related nervous system disorders. The company markets Ampyra (dalfampridine), a potassium channel blocker approved as a treatment to improve walking in patients with MS. Increasing uptake of Ampyra has enhanced Acorda's top-line growth. However, lengthening drug approval times could affect Acorda's prospective products' commercial viability. Strength Marketing capabilities increases healthcare offerings Significant revenue growth strengthening Acorda's cash position Ampyra boosting Acorda's top-line growth Weakness Dependence on single manufacturer for Zanaflex could result in supply side constraints Opportunity Growing CNS Disorders market increases market share Increase in the pain management drugs market Threat Costly and time consuming development process could affect prospective products' commercial viability Pricing pressure by third party payers could affect Acorda's margins [Show More]

Last updated: 2 years ago

Preview 1 out of 9 pages

Buy Now

Instant download

We Accept: